Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 ...
AZoLifeSciences on MSN
Syntax Bio develops CRISPR technology to program stem cell gene activity
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback